Galapagos N.V.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Henry Gosebruch
- Full Time Employees
- 704
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Generaal De Wittelaan L11 A3 Mechelen Belgium 2800
- IPO Date
- Feb 27, 2012
- CIK
- 0001421876
- Website
- glpg.com
- Similar Companies
- Business
- Galapagos NV (GLPG), a clinical-stage biotechnology company founded in 1999 and headquartered in Mechelen, Belgium, develops transformative therapies addressing high unmet medical needs in oncology and immunology through its decentralized cell therapy manufacturing platform and small molecule programs; core offerings include next-generation CAR-T cell therapies such as GLPG5101 advancing toward pivotal development, uza-cel (a MAGE-A4 directed TCR T-cell therapy in collaboration with Adaptimmune for head and neck cancer and solid tumors), multi-targeting stem-like early memory cell therapies produced in median seven days vein-to-vein via scalable decentralized manufacturing units (DMUs), and small molecule assets like the Phase 2 TYK2 inhibitor GLPG3667 for systemic lupus erythematosus, dermatomyositis, and other autoimmune indications, with operations spanning Europe, the United States, and China. The company maintains end-to-end capabilities from discovery to patient delivery, including fully human antibody-based biologics platforms acquired through the 2022 purchases of CellPoint and AboundBio, and supports its pipeline via partnerships with Lonza (Cocoon platform), Thermo Fisher Scientific (ultra-rapid PCR sterility testing), Catalent, NecstGen, and Moffitt Cancer Center for DMU expansion in key regions. In January 2025, Galapagos announced plans to separate into two publicly traded entities by mid-2025, with the parent company retaining global cell therapy leadership in oncology funded by approximately €500 million in cash to 2028, and SpinCo receiving €2.45 billion to pursue innovative medicines in oncology, immunology, and virology via transformative transactions; it is actively seeking partners for its small molecules portfolio while establishing China operations to accelerate cell therapy development and projecting 2025 year-end cash of €2.975-€3.025 billion with annual burn of €175-€225 million post-separation.
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026
Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average – Time to Sell?
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Raad van Bestuur
Galapagos Announces Nomination of Gino Santini to its Board of Directors
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings
Galapagos publiceert 2025 jaarverslag en kondigt de Gewone (jaarlijkse) en Buitengewone Algemene Vergaderingen aan
Stock Market Today (LIVE): Market Rally Fizzles as Oil Rebounds; Smithfield Foods Hams It Up
Breakfast News: Gilead Bets Big on Its Next Phase
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
Galapagos Receives Transparency Notification from Bank of America
Galapagos Receives Transparency Notifications from Bank of America
Galapagos Creates New Subscription Right Plan
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
Galapagos Receives Transparency Notifications from Bank of America
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update